| Product Code: ETC9956479 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Kingdom (UK) Thyroid Cancer Drug Market Overview |
3.1 United Kingdom (UK) Country Macro Economic Indicators |
3.2 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, 2021 & 2031F |
3.3 United Kingdom (UK) Thyroid Cancer Drug Market - Industry Life Cycle |
3.4 United Kingdom (UK) Thyroid Cancer Drug Market - Porter's Five Forces |
3.5 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.7 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 United Kingdom (UK) Thyroid Cancer Drug Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of thyroid cancer in the UK |
4.2.2 Technological advancements in the development of thyroid cancer drugs |
4.2.3 Growing awareness about early diagnosis and treatment options for thyroid cancer |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval in the UK |
4.3.2 High costs associated with research and development of new thyroid cancer drugs |
4.3.3 Limited availability of effective targeted therapies for thyroid cancer treatment in the UK |
5 United Kingdom (UK) Thyroid Cancer Drug Market Trends |
6 United Kingdom (UK) Thyroid Cancer Drug Market, By Types |
6.1 United Kingdom (UK) Thyroid Cancer Drug Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Papillary Thyroid Cancer, 2021- 2031F |
6.1.4 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Follicular Thyroid Cancer, 2021- 2031F |
6.1.5 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Hurthle Cell Cancer, 2021- 2031F |
6.1.6 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Medullary Thyroid Cancer (MTC), 2021- 2031F |
6.1.7 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Anaplastic Thyroid Cancer, 2021- 2031F |
6.2 United Kingdom (UK) Thyroid Cancer Drug Market, By Drug Type |
6.2.1 Overview and Analysis |
6.2.2 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Thyroid Desiccated, 2021- 2031F |
6.2.3 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Sorafenib, 2021- 2031F |
6.2.4 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Thyrotropin Alfa, 2021- 2031F |
6.2.5 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Vandetanib, 2021- 2031F |
6.2.6 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Doxorubicin, 2021- 2031F |
6.2.7 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Cabozantinib, 2021- 2031F |
6.2.8 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Sodium Iodide I-131, 2021- 2031F |
6.2.9 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Sodium Iodide I-131, 2021- 2031F |
6.2.10 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Dabrafenib, 2021- 2031F |
6.3 United Kingdom (UK) Thyroid Cancer Drug Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Injectable, 2021- 2031F |
6.3.4 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United Kingdom (UK) Thyroid Cancer Drug Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.4 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.5 United Kingdom (UK) Thyroid Cancer Drug Market Revenues & Volume, By Others, 2021- 2031F |
7 United Kingdom (UK) Thyroid Cancer Drug Market Import-Export Trade Statistics |
7.1 United Kingdom (UK) Thyroid Cancer Drug Market Export to Major Countries |
7.2 United Kingdom (UK) Thyroid Cancer Drug Market Imports from Major Countries |
8 United Kingdom (UK) Thyroid Cancer Drug Market Key Performance Indicators |
8.1 Patient survival rates post-treatment |
8.2 Time taken for regulatory approval of new thyroid cancer drugs |
8.3 Adoption rate of innovative treatment approaches for thyroid cancer in the UK |
9 United Kingdom (UK) Thyroid Cancer Drug Market - Opportunity Assessment |
9.1 United Kingdom (UK) Thyroid Cancer Drug Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 United Kingdom (UK) Thyroid Cancer Drug Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.3 United Kingdom (UK) Thyroid Cancer Drug Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 United Kingdom (UK) Thyroid Cancer Drug Market Opportunity Assessment, By End User, 2021 & 2031F |
10 United Kingdom (UK) Thyroid Cancer Drug Market - Competitive Landscape |
10.1 United Kingdom (UK) Thyroid Cancer Drug Market Revenue Share, By Companies, 2024 |
10.2 United Kingdom (UK) Thyroid Cancer Drug Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here